S
Sunil Reddy
Researcher at Stanford University
Publications - 64
Citations - 4706
Sunil Reddy is an academic researcher from Stanford University. The author has contributed to research in topics: Pembrolizumab & Melanoma. The author has an hindex of 22, co-authored 58 publications receiving 3650 citations.
Papers
More filters
Journal ArticleDOI
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Paul Nghiem,Shailender Bhatia,Evan J. Lipson,Ragini R. Kudchadkar,Natalie J. Miller,Lakshmanan Annamalai,Sneha Berry,Elliot Chartash,Adil Daud,Steven P. Fling,Philip Friedlander,Harriet M. Kluger,Holbrook E Kohrt,Lisa Lundgren,Kim Margolin,Alan Mitchell,Thomas Olencki,Drew M. Pardoll,Sunil Reddy,E. Shantha,William H. Sharfman,Elad Sharon,Lynn Shemanski,Michi M. Shinohara,Joel C. Sunshine,Janis M. Taube,John A. Thompson,John A. Thompson,Steven M. Townson,Jennifer H. Yearley,Suzanne L. Topalian,Martin A. Cheever,Martin A. Cheever +32 more
TL;DR: First-line therapy with pembrolizumab in patients with advanced Merkel-cell carcinoma was associated with an objective response rate of 56% and effectiveness was correlated with tumor viral status, as assessed by serologic and immunohistochemical testing.
Journal ArticleDOI
Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma
Sean Whittaker,Marie-France Demierre,Ellen J. Kim,Alain H. Rook,Adam Lerner,Madeleine Duvic,Julia Scarisbrick,Sunil Reddy,Tadeusz Robak,Jürgen C. Becker,Alexey Samtsov,William McCulloch,Youn H. Kim +12 more
TL;DR: Romidepsin has significant and sustainable single-agent activity (including improvement in pruritus) and an acceptable safety profile, making it an important therapeutic option for treatment refractory CTCL.
Journal ArticleDOI
Management of Immunotherapy-Related Toxicities, Version 1.2019.
John A. Thompson,Bryan J. Schneider,Julie R. Brahmer,Stephanie Andrews,Philippe Armand,Shailender Bhatia,Lihua E. Budde,Luciano J. Costa,Marianne Davies,David Dunnington,Marc S. Ernstoff,Matthew J. Frigault,Brianna Hoffner,Christopher J. Hoimes,Mario E. Lacouture,Frederick L. Locke,Matthew A. Lunning,Nisha Mohindra,Jarushka Naidoo,Anthony J. Olszanski,Olalekan O. Oluwole,Sandip Pravin Patel,Sunil Reddy,Mabel Ryder,Bianca Santomasso,Scott Shofer,Jeffrey A. Sosman,Momen M. Wahidi,Yinghong Wang,Alyse Johnson-Chilla,Jillian L. Scavone +30 more
TL;DR: The content featured in this issue is an excerpt of the recommendations for managing toxicity related to immune checkpoint blockade and a review of existing evidence.
Journal ArticleDOI
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.
John A. Thompson,Bryan J. Schneider,Julie R. Brahmer,Stephanie Andrews,Philippe Armand,Shailender Bhatia,Lihua E. Budde,Luciano J. Costa,Marianne Davies,David Dunnington,Marc S. Ernstoff,Matthew J. Frigault,Benjamin H. Kaffenberger,Matthew A. Lunning,Suzanne McGettigan,Jordan P. McPherson,Nisha Mohindra,Jarushka Naidoo,Anthony J. Olszanski,Olalekan O. Oluwole,Sandip Pravin Patel,Nathan A. Pennell,Sunil Reddy,Mabel Ryder,Bianca Santomasso,Scott Shofer,Jeffrey A. Sosman,Yinghong Wang,Ryan M. Weight,Alyse Johnson-Chilla,Griselda Zuccarino-Catania,Anita M. Engh +31 more
TL;DR: The NCCN Guidelines for Management of Immunotherapy-Related Toxicities provide interdisciplinary guidance on the management of immune-related adverse events (irAEs) resulting from cancer immunotherapy as discussed by the authors.
Journal ArticleDOI
Cd30+ cutaneous lymphoproliferative disorders: The stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma ☆
TL;DR: The single-center experience of Stanford University, Stanford, Calif, demonstrates CD30+CLPDs have an overall excellent prognosis; however, cases of PCALCL with poor outcome do exist.